Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | PTGIS | Q16647 | 1/20 | 0.32 |
| ▸ | FABP4 | P15090 | 1/20 | 0.32 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.32 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30723887 | 0.82 | RXRA (0.31) | RXRARXRBRXRG | |
| SCHEMBL24179526 | 0.82 | RXRA (0.31) | RXRARXRBRXRG | |
| SCHEMBL24179545 | 0.80 | RXRA (0.46) | RXRARXRBRXRGTBXAS1MGLL | |
| SCHEMBL30723993 | 0.77 | KDM4E (0.30) | KDM4E | |
| SCHEMBL16634070 | 0.75 | CYP4F2 (0.37) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL30724102 | 0.75 | CYP4F2 (0.37) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL15208830 | 0.70 | RXRA (0.38) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL15278356 | 0.70 | KRAS (0.33) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL31190681 | 0.70 | CYP4F2 (0.35) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL31190591 | 0.70 | CYP4F2 (0.35) | RXRARXRBRXRGCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024006776-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND MEDICAL USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230242507-A1 | INDAZOLE-FUSED CYCLIC COMPOUND | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230242507-A1 | INDAZOLE-FUSED CYCLIC COMPOUND | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (CN) | 2023-08-03 | — | — | US | disclosed |
| WO-2022001971-A1 | INDAZOLE-FUSED CYCLIC COMPOUND | 南京明德新药研发有限公司 | 2022-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242507-A1 | INDAZOLE-FUSED CYCLIC COMPOUND | SLC5A11, CYP11B2, CYP4F11 | RXRA 3699/4885RXRB 3804/4885RXRG 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.